Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for Relapsed/Refractory Plasma Cell Tumors
NCT04665076Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of senl-103 in plasma cell neoplasm, sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Started Oct 2020; status: recruiting.
02
Drugs
senl-103
03
Conditions
plasma cell neoplasm
Beyond the preview
Go deeper on NCT04665076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665076.